Key points from this week’s report:
Please refer to the attached PDF for the full report.
- With the prospects of September rate cuts back on the table, the U.S. markets have staged a strong recovery and are trading back near highs. With the labor market weakening in the Eurozone and wage growth slowing in the past three months through June, markets expect a second rate cut by the ECB when the policymakers meet in September. Behind the optimism of rate cuts in Europe and the U.S., the Stoxx 600 has rallied from August 5 lows to reclaim its key moving averages and now trades 141 bps below the early June highs. Nevertheless, most of the 16 indices we cover in the region are still in a Rally Attempt. Without a follow-through day to confirm a new uptrend, we recommend a selective approach to adding names.
- With the markets staging a recovery, leadership has emerged in pockets. For the second consecutive week, the number of stocks breaking out has improved, jumping to 481 from the prior week’s 140 but still far behind mid-July levels of 741 and early May levels of 1,212 when the Stoxx 600 was breaking into new highs. The number of stocks trading near the pivot of their bases has nearly doubled to 3.7K from 1.9K two weeks ago, while the number of bases that have failed has remained stable at ~800, down from 1,334 levels two weeks prior.
Sector Score Cards – Stocks of Interest (Top-rated names with the best technical setups – refer to pages 9–20):
- Capital Equipment: Rolls-Royce Holdings (RR.GB, FL constituent), NKT (NKT.DK, FL constituent), RELX (REL.GB, FL constituent).
- Consumer Cyclical: Ferrari (RACE.IT, FL constituent).
- Consumer Staples: Premier Food (PFD.GB, FL constituent), AAK (AAK.SE), Galderma (GALD.CH, FL constituent).
- Financials: 3i Group (III.GB, FL constituent), Swissquote ‘R’ (SQN.CH, FL constituent).
- Healthcare: Swedish Orphan Biovitrum (SOBI.SE, FL constituent), Biotage (BIOT.SE, FL constituent), Lonza Group (LONN.CH, FL constituent), Alk-Abello (ALK.DK).
- Retail: Inditex (IND.ES; FL constituent).
European Focus List Update: